Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report-Reference-Cited by-同舟云学术

Severe pancytopenia caused by trifluridine/tipiracil in patients with metastatic colorectal cancer and an impaired renal function: A case report

Published:2022-03 Issue:3 Volume:10 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Shibutani Masatsune¹^ORCID,Okazaki Yuki¹,Kashiwagi Shinichiro²,Nagahara Hisashi¹,Fukuoka Tatsunari¹,Iseki Yasuhito¹,Maeda Kiyoshi³,Hirakawa Kosei¹,Ohira Masaichi¹

Affiliation:

1. Department of Gastroenterological Surgery Osaka City University Graduate School of Medicine Osaka Japan

2. Department of Breast and Endocrine Surgery Osaka City University Graduate School of Medicine Osaka Japan

3. Department of Gastroenterological Surgery Osaka City General Hospital Osaka Japan

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.5544

Reference14 articles.

1. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

3. Integrated safety summary for trifluridine/tipiracil (TAS-102)

4. TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study

5. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2022-06